Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy

Dual role of protein tyrosine phosphatase 1B in the progression and reversion of non-alcoholic steatohepatitis

(2018) Águeda González-Rodríguez et al.   Molecular Metabolism

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Hepatostat: Liver regeneration and normal liver tissue maintenance

(2017) George K. Michalopoulos   HEPATOLOGY

A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice

(2017) M. Pilar Valdecantos et al.   HEPATOLOGY

Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease

(2017) Hashimoto Yoshitaka et al.   MEDICINE

Mechanisms of hepatic stellate cell activation

(2017) Takuma Tsuchida et al.   Nature Reviews Gastroenterology & Hepatology

Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice

(2017) Hani Jouihan et al.   Molecular Metabolism

GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway

(2016) Qin He et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure

(2016) Kim M.C. van Mierlo et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Management of NAFLD: a stage-based approach

(2016) Mary E. Rinella et al.   Nature Reviews Gastroenterology & Hepatology

GLP-1 contributes to increases in PGC-1α expression by downregulating miR-23a to reduce apoptosis

(2015) Chi Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States

(2015) Robert J. Wong et al.   GASTROENTEROLOGY

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop

(2015) Arun J. Sanyal et al.   HEPATOLOGY

Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management

(2015) Kelly J. Lafaro et al.   Gastroenterology Research and Practice

Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets

(2014) Ffolliott M. Fisher et al.   GASTROENTEROLOGY

Roles for Chemokines in Liver Disease

(2014) Fabio Marra et al.   GASTROENTEROLOGY

Exendin-4, a glucagon-like peptide-1 receptor agonist, modulates hepatic fatty acid composition and Δ-5-desaturase index in a murine model of non-alcoholic steatohepatitis

(2014) TAKUMI KAWAGUCHI et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Nonalcoholic Steatohepatits and Liver Steatosis Modify Partial Hepatectomy Recovery

(2014) Steffi Hoppe et al.   JOURNAL OF INVESTIGATIVE SURGERY

Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect

(2014) Nirav Dhanesha et al.   Pharmacological Reports

Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD

(2014) Á González-Rodríguez et al.   Cell Death & Disease

GLP-1-derived nonapeptide GLP-1(28–36)amide represses hepatic gluconeogenic gene expression and improves pyruvate tolerance in high-fat diet-fed mice

(2013) Wilfred Ip et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration

(2013) Y Wang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications

(2013) Giovanni Targher et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GLP-1R agonist may activate pancreatic stellate cells to induce rat pancreatic tissue lesion

(2013) Yongchao Yang et al.   PANCREATOLOGY

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

(2012) James L. Trevaskis et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice

(2012) Naim Panjwani et al.   ENDOCRINOLOGY

Exendin-4 Improves Steatohepatitis by Increasing Sirt1 Expression in High-Fat Diet-Induced Obese C57BL/6J Mice

(2012) Jinmi Lee et al.   PLoS One

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

(2011) Jamie E. Mells et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

(2011) Michael R. Charlton et al.   GASTROENTEROLOGY

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

(2011) Gianluca Svegliati-Baroni et al.   LIVER INTERNATIONAL

Scraping fibrosis: Expressway to the core of fibrosis

(2011) Wajahat Z Mehal et al.   NATURE MEDICINE

GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy

(2011) Shvetank Sharma et al.   PLoS One

GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet

(2010) Edwin T. Parlevliet et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

(2010) Wolfgang Glaesner et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease

(2010) Jody Dushay et al.   GASTROENTEROLOGY

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY

GLP-1 (9–36) Amide Metabolite Suppression of Glucose Production in Isolated Mouse Hepatocytes

(2010) E. Tomas et al.   HORMONE AND METABOLIC RESEARCH

Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride

(2010) Huating Li et al.   JOURNAL OF HEPATOLOGY